Surgical Debulking of Ovarian Cancer: What Difference Does It Make?

Overview

Journal Rev Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2011 Mar 3

PMID 21364862

Citations 38

Authors

John O Schorge

Christopher McCann

Marcela G Del Carmen

Affiliations

Soon will be listed here.

Abstract

Three-quarters of women who are newly diagnosed with invasive epithelial ovarian cancer present with stage III to IV disease. Recent data on the efficacy of neoadjuvant chemotherapy have served to challenge the conventional dogma that the preferred initial treatment is surgical debulking. Most of these patients will achieve remission regardless of initial treatment, but 80% to 90% of patients will ultimately relapse. The timing and clinical benefit of a second debulking operation is even more contentious. This article focuses on the recent debate of when or if patients with ovarian cancer should undergo aggressive surgical resection of bulky disease.

Citing Articles

The Influence of Inflammatory and Nutritional Status on the Long-Term Outcomes in Advanced Stage Ovarian Cancer.

Bacalbasa N, Petrea S, Gaspar B, Pop L, Varlas V, Hasegan A Cancers (Basel). 2024; 16(14).

PMID: 39061143 PMC: 11274520. DOI: 10.3390/cancers16142504.

Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment.

Pampeno C, Opp S, Hurtado A, Meruelo D Int J Mol Sci. 2024; 25(5).

PMID: 38474178 PMC: 10932354. DOI: 10.3390/ijms25052925.

CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer.

Nasiri F, Farrokhi K, Safarzadeh Kozani P, Mahboubi Kancha M, Dashti Shokoohi S, Safarzadeh Kozani P Front Immunol. 2023; 14:1302307.

PMID: 38146364 PMC: 10749368. DOI: 10.3389/fimmu.2023.1302307.

Impact of obese patients in ovarian cancer surgery on postoperative wound complications: A meta-analysis.

Huang X, Du S, Wang Q, Yang C, Liu X, Chen K Int Wound J. 2023; 21(4):e14439.

PMID: 38064172 PMC: 10957721. DOI: 10.1111/iwj.14439.

Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas.

Torkildsen C, Vestrheim Thomsen L, Sande R, Krakstad C, Stefansson I, Lamark E Cancer Med. 2023; 12(13):14183-14195.

PMID: 37191035 PMC: 10358208. DOI: 10.1002/cam4.6085.

References

Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C . Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg. 2003; 197(6):955-63. DOI: 10.1016/j.jamcollsurg.2003.06.004. View

Schwartz P, Rutherford T, Chambers J, Kohorn E, Thiel R . Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol. 1999; 72(1):93-9. DOI: 10.1006/gyno.1998.5236. View

Bristow R, Eisenhauer E, Santillan A, Chi D . Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2006; 104(2):480-90. DOI: 10.1016/j.ygyno.2006.11.002. View

Rose P, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin S . Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004; 351(24):2489-97. DOI: 10.1056/NEJMoa041125. View

Hoskins W, Bundy B, Thigpen J, Omura G . The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1992; 47(2):159-66. DOI: 10.1016/0090-8258(92)90100-w. View

Berchuck A, Iversen E, Lancaster J, Dressman H, West M, Nevins J . Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol. 2004; 190(4):910-25. DOI: 10.1016/j.ajog.2004.02.005. View

Bristow R, Peiretti M, Gerardi M, Zanagnolo V, Ueda S, Diaz-Montes T . Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcome. Gynecol Oncol. 2009; 114(2):173-7. DOI: 10.1016/j.ygyno.2009.05.004. View

Bertelsen K . Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol. 1990; 38(2):203-9. DOI: 10.1016/0090-8258(90)90042-j. View

Morrison J, Swanton A, Collins S, Kehoe S . Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2007; (4):CD005343. DOI: 10.1002/14651858.CD005343.pub2. View

10.

Eisenhauer E, Abu-Rustum N, Sonoda Y, Levine D, Poynor E, Aghajanian C . The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006; 103(3):1083-90. DOI: 10.1016/j.ygyno.2006.06.028. View

11.

Shih K, Chi D, Barakat R, Leitao Jr M . Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2009; 116(3):364-9. DOI: 10.1016/j.ygyno.2009.10.047. View

12.

Delgado G, Oram D, Petrilli E . Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol. 1984; 18(3):293-8. DOI: 10.1016/0090-8258(84)90040-4. View

13.

Chan J, Kapp D, Shin J, Husain A, Teng N, Berek J . Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol. 2007; 109(6):1342-50. DOI: 10.1097/01.AOG.0000265207.27755.28. View

14.

Aletti G, Dowdy S, Podratz K, Cliby W . Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2005; 100(2):283-7. DOI: 10.1016/j.ygyno.2005.08.027. View

15.

Hoskins W, McGuire W, Brady M, Homesley H, Creasman W, Berman M . The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994; 170(4):974-9; discussion 979-80. DOI: 10.1016/s0002-9378(94)70090-7. View

16.

Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V . Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med. 2009; 14(12):2748-59. PMC: 3822725. DOI: 10.1111/j.1582-4934.2009.00911.x. View

17.

van der Burg M, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G . The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995; 332(10):629-34. DOI: 10.1056/NEJM199503093321002. View

18.

Chi D, Eisenhauer E, Zivanovic O, Sonoda Y, Abu-Rustum N, Levine D . Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114(1):26-31. DOI: 10.1016/j.ygyno.2009.03.018. View

19.

Schorge J, Wingo S, Bhore R, Heffernan T, Lea J . Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2009; 108(2):123-7. DOI: 10.1016/j.ijgo.2009.08.034. View

20.

Hacker N, Berek J, Lagasse L, Nieberg R, Elashoff R . Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983; 61(4):413-20. View